Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial)
Authors:
- Leonie HaverkampLHLeonie Haverkamp
- Hylke Jf BrenkmanHBHylke Jf Brenkman
- Maarten Fj SeesingMSMaarten Fj Seesing
- Suzanne S GisbertzSGSuzanne S Gisbertz
- Mark I van Berge HenegouwenMark I van Berge Henegouwen
- Misha Dp LuyerMisha Dp Luyer
- Grard AP NieuwenhuijzenGNGrard AP Nieuwenhuijzen
- Bas Pl WijnhovenBas Pl Wijnhoven
- Jan Jb van LanschotJLJan Jb van Lanschot
- Wobbe O de SteurWSWobbe O de Steur
- Henk H HartgrinkHHHenk H Hartgrink
- Jan Hmb StootJSJan Hmb Stoot
Open Access
- 29 July 2015
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 1-7
Abstract
For gastric cancer patients, surgical resection with en-bloc lymphadenectomy is the cornerstone of curative treatment. Open gastrectomy has long been the preferred surgical approach worldwide. However, this procedure is associated with considerable morbidity. Several meta-analyses have shown an advantage in short-term outcomes of laparoscopic gastrectomy compared to open procedures, with similar oncologic outcomes. However, it remains unclear whether the results of these Asian studies can be extrapolated to the Western population. In this trial from the Netherlands, patients with resectable gastric cancer will be randomized to laparoscopic or open gastrectomy. The study is a non-blinded, multicenter, prospectively randomized controlled superiority trial. Patients (≥18 years) with histologically proven, surgically resectable (cT1-4a, N0-3b, M0) gastric adenocarcinoma and European Clinical Oncology Group performance status 0, 1 or 2 are eligible to participate in the study after obtaining informed consent. Patients (n = 210) will be included in one of the ten participating Dutch centers and are randomized to either laparoscopic or open gastrectomy. The primary outcome is postoperative hospital stay (days). Secondary outcome parameters include postoperative morbidity and mortality, oncologic outcomes, readmissions, quality of life and cost-effectiveness. In this randomized controlled trial laparoscopic and open gastrectomy are compared in patients with resectable gastric cancer. It is expected that laparoscopic gastrectomy will result in a faster recovery of the patient and a shorter hospital stay. Secondly, it is expected that laparoscopic gastrectomy will be associated with a lower postoperative morbidity, less readmissions, higher cost-effectiveness, better postoperative quality of life, but with similar mortality and oncologic outcomes, compared to open gastrectomy. The study started on 1 December 2014. Inclusion and follow-up will take 3 and 5 years respectively. Short-term results will be analyzed and published after discharge of the last randomized patient. NCT02248519Keywords
This publication has 29 references indexed in Scilit:
- Meta-Analysis of D1 Versus D2 Gastrectomy for Gastric AdenocarcinomaAnnals of Surgery, 2011
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Long-Term Benefits of Roux-en-Y Pouch Reconstruction After Total GastrectomyAnnals of Surgery, 2008
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006
- Gastric cancer in the East: same disease, different patientBritish Journal of Surgery, 2005
- Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancerEuropean Journal of Cancer, 2004
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group TrialJournal of Clinical Oncology, 2004
- Labor and Health Status in Economic Evaluation of Health Care: The Health and Labor QuestionnaireInternational Journal of Technology Assessment in Health Care, 1996
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993